| 07/22/2026 7:37 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 8:30 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/25/2026 8:25 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/17/2026 3:30 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2026 3:30 PM | Ben-Noon Alon (1901198) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 8:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/09/2026 9:13 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/08/2026 8:05 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/28/2026 2:38 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/24/2026 8:20 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/06/2026 8:20 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for NRSNW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 04/03/2026 8:27 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/01/2026 3:25 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/01/2026 3:26 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 3:16 PM | Mandil-Levin Revital (2125058) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/31/2026 8:29 AM | NeuroSense Therapeutics (1875091) Filer | Form 20-F Registration statement / Annual report / Transition report | |
| 03/31/2026 8:29 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/30/2026 7:49 AM | Binder Hagit (2118272) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/30/2026 7:51 AM | Ben-Noon Alon (1901198) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/24/2026 9:11 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/18/2026 2:35 PM | Binder Hagit (2118272) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:35 PM | Leuchtenberger Mark (1303315) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:35 PM | Golan Roy (1999257) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:36 PM | Claiborne Cary J (1370930) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:36 PM | NeuroSense Therapeutics (1875091) Issuer Tracik Ferenc (2120172) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/16/2026 11:27 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/11/2026 7:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/18/2026 8:21 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/09/2026 8:30 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/29/2026 4:28 PM | NeuroSense Therapeutics (1875091) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 01/06/2026 4:27 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/22/2025 10:49 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/08/2025 7:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/04/2025 7:39 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/26/2025 3:15 PM | NeuroSense Therapeutics (1875091) Filer | Form 424B3 | |
| 11/25/2025 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |
| 11/21/2025 5:36 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/28/2025 3:26 PM | NeuroSense Therapeutics (1875091) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 10/06/2025 8:06 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/25/2025 8:23 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/10/2025 1:35 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (Ad) Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. Get the name and ticker of Louis Navellier's #1 AI stock free |
| 09/04/2025 7:59 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/04/2025 8:01 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/02/2025 7:36 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/21/2025 3:56 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/20/2025 8:31 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/18/2025 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |
| 08/18/2025 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |
| 08/08/2025 3:15 PM | NeuroSense Therapeutics (1875091) Filer | Form 424B5 | |
| 08/01/2025 8:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |